Sliwens: Withdrawal of the marketing authorisation application


On 18 December 2009, Sanofi-Aventis officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Sliwens, for use in adults with chronic (long-term) insomnia who have difficulty staying asleep.

  • List item

    Questions and answers on withdrawal of marketing authorisation application for Sliwens (eplivanserin) (PDF/50.43 KB)

    First published: 20/01/2010
    Last updated: 20/01/2010

  • Key facts

    Product number
    Date of withdrawal
    Company making the application
    Sanofi Aventis
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating